Ildong Pharmaceutical Co., Ltd.
KRX:249420.KS
14050 (KRW) • At close September 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 600,757.84 | 637,714.49 | 560,131.626 | 561,845.1 | 517,467.682 | 503,907.355 | 460,650.815 | 201,343.779 |
| Cost of Revenue
| 393,218.782 | 401,371.108 | 340,693.101 | 323,431.207 | 285,112.117 | 248,752.318 | 234,420.524 | 104,047.573 |
| Gross Profit
| 207,539.058 | 236,343.382 | 219,438.525 | 238,413.893 | 232,355.565 | 255,155.037 | 226,230.291 | 97,296.207 |
| Gross Profit Ratio
| 0.345 | 0.371 | 0.392 | 0.424 | 0.449 | 0.506 | 0.491 | 0.483 |
| Reseach & Development Expenses
| 95,018.071 | 109,895.105 | 96,523.856 | 60,180.879 | 48,497.439 | 46,458.131 | 33,362.489 | 12,506.594 |
| General & Administrative Expenses
| 13,387.315 | 13,967.123 | 12,413.955 | 11,573.831 | 15,048.858 | 17,207.39 | 17,181.517 | 6,349.47 |
| Selling & Marketing Expenses
| 68,863.486 | 101,103.418 | 82,968.133 | 84,960.654 | 87,807.08 | 80,021.98 | 73,760.773 | 28,933.174 |
| SG&A
| 165,938.563 | 115,070.541 | 95,382.088 | 96,534.485 | 102,855.938 | 97,229.37 | 90,942.29 | 35,282.644 |
| Other Expenses
| 1,910.007 | 84,711.059 | 81,912.291 | 75,065.686 | 82,374.715 | 1,479.128 | 1,037.999 | 898.456 |
| Operating Expenses
| 260,956.634 | 309,676.705 | 273,818.235 | 231,781.05 | 233,728.092 | 226,811.795 | 200,869.427 | 82,503.842 |
| Operating Income
| -53,417.576 | -73,333.323 | -54,379.71 | 6,632.844 | -1,255.465 | 28,343.243 | 25,360.864 | 14,792.365 |
| Operating Income Ratio
| -0.089 | -0.115 | -0.097 | 0.012 | -0.002 | 0.056 | 0.055 | 0.073 |
| Total Other Income Expenses Net
| -40,854.794 | -46,490.073 | -86,825.332 | -16,356.899 | -21,378.958 | -11,905.058 | -4,938.937 | -778.128 |
| Income Before Tax
| -94,272.37 | -119,823.396 | -141,205.041 | -9,724.055 | -22,634.423 | 16,438.184 | 20,421.927 | 14,014.236 |
| Income Before Tax Ratio
| -0.157 | -0.188 | -0.252 | -0.017 | -0.044 | 0.033 | 0.044 | 0.07 |
| Income Tax Expense
| -13,311.684 | 22,346.154 | -40,236.573 | 3,295.104 | -9,190.839 | 3,717.494 | 580.885 | 1,435.543 |
| Net Income
| -78,928.206 | -142,169.55 | -100,968.469 | -13,019.16 | -13,443.583 | 12,720.69 | 19,841.042 | 12,578.693 |
| Net Income Ratio
| -0.131 | -0.223 | -0.18 | -0.023 | -0.026 | 0.025 | 0.043 | 0.062 |
| EPS
| -2,920.01 | -5,396.73 | -4,244.99 | -547.34 | -565.08 | 534.63 | 876.19 | 610.39 |
| EPS Diluted
| -2,920.01 | -5,396.73 | -4,244.99 | -547.34 | -565.08 | 534.29 | 876.19 | 610.39 |
| EBITDA
| -25,098.9 | -43,553.053 | -23,621.155 | 35,723.662 | 26,663.208 | 53,916.942 | 44,962.307 | 23,231.088 |
| EBITDA Ratio
| -0.042 | -0.068 | -0.042 | 0.064 | 0.052 | 0.107 | 0.098 | 0.115 |